Paul Tudor Jones Abb Vie Inc. Call Options Transaction History

Tudor Investment Corp Et Al

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $950,272 - $1.16 Million	-5,800 Reduced 22.83%	19,600 $3.87 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $8.81 Million - $10.3 Million	-56,900 Reduced 69.14%	25,400 $4.36 Million
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $735,172 - $837,660	4,600 Added 5.92%	82,300 $15 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $10.4 Million - $11.7 Million	75,600 Added 3600.0%	77,700 $12 Million
Q3 2023 Nov 15, 2023	BUY	$133.59 - $154.65 $280,539 - $324,765	2,100 New	2,100 $313,000

3,855

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.